, Tracking Stock Market Picks
Enter Symbol:

Neutral MDVN
down 17.09 %

MEDIVATION INC (MDVN) downgraded to Neutral by Hapoalim

Posted on: Wednesday,  Mar 3, 2010  9:25 AM ET by Hapoalim

Hapoalim rated Neutral MEDIVATION INC (NASDAQ: MDVN) on 03/03/2010. Previously Hapoalim rated Outperform MEDIVATION INC (NASDAQ: MDVN) on 03/05/2009., when
the stock price was $7.78. Since then, MEDIVATION INC has lost 17.10% as of 03/03/2010's recent price of $6.45.
If you would have followed the previous Hapoalim's recommendation on MDVN, you would have lost 17.09% of your investment in 363 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Hapoalim Securities redistributes fundamental research on Israeli growth companies written by professional analysts employed by our affiliate, Bank Hapoalim B.M. The research product has an emphasis and strength in diversified sectors, including technology, communications and pharmaceutical companies. The strength of Hapoalim's relationships with these companies allows us to provide clients with access to the managements of the companies as necessary.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/3/2010 9:25 AM Hold
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD down  -65.73 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2009 9:25 AM Buy
7.78 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy